Method to control leukocyte extravasation

Novel antibodies that recognize endothelial cell surface molecules or synovial-specific leukocyte homing receptors and block leukocyte extravasation are provided. These antibodies recognize either tissue-specific endothelial cell surface molecules or a synovial-specific leukocyte cell surface glycop...

Full description

Saved in:
Bibliographic Details
Main Authors BUTCHER, EUGENE C, JALKANEN, SIRPA T
Format Patent
LanguageEnglish
French
German
Published 30.11.1994
Edition5
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
ENZYMOLOGY
FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROCESSES USING MICROORGANISMS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:Novel antibodies that recognize endothelial cell surface molecules or synovial-specific leukocyte homing receptors and block leukocyte extravasation are provided. These antibodies recognize either tissue-specific endothelial cell surface molecules or a synovial-specific leukocyte cell surface glycoprotein and block lymphocyte migration from the blood into tissues such as mucosal lymphoid organs, peripheral lymph nodes, and synovium. Also described are novel endothelial cell surface proteins involved in leukocyte extravasation, having a molecular weight of approximately 58,000 to 69,000 daltons, which express a tissue-specific determinant, as well as a synovial-specific leukocyte glycoprotein of approximately 90,000 daltons. The antibodies are used in compositions to treat individuals having a disease or inflammation-associated pathology in which leukocyte extravasation plays a role.
Bibliography:Application Number: EP19880307397